741 related articles for article (PubMed ID: 31830822)
1. Outcomes and Anticoagulation Use After Catheter Ablation for Atrial Fibrillation.
Freeman JV; Shrader P; Pieper KS; Allen LA; Chan PS; Fonarow GC; Gersh BJ; Kowey PR; Mahaffey KW; Naccarelli G; Reiffel JA; Singer DE; Go AS; Hylek EM; Steinberg BA; Peterson ED; Piccini JP
Circ Arrhythm Electrophysiol; 2019 Dec; 12(12):e007612. PubMed ID: 31830822
[TBL] [Abstract][Full Text] [Related]
2. Current Status and Clinical Outcomes of Oral Anticoagulant Discontinuation After Ablation for Atrial Fibrillation in Japan - Findings From the AF Frontier Ablation Registry.
Okumura Y; Nagashima K; Arai M; Watanabe R; Yokoyama K; Matsumoto N; Otsuka T; Suzuki S; Hirata A; Murakami M; Takami M; Kimura M; Fukaya H; Nakahara S; Kato T; Shimizu W; Iwasaki YK; Hayashi H; Harada T; Nakajima I; Okumura K; Koyama J; Tokuda M; Yamane T; Momiyama Y; Tanimoto K; Soejima K; Nonoguchi N; Ejima K; Hagiwara N; Harada M; Sonoda K; Inoue M; Kumagai K; Hayashi H; Satomi K; Yazaki Y; Watari Y;
Circ J; 2019 Nov; 83(12):2418-2427. PubMed ID: 31619591
[TBL] [Abstract][Full Text] [Related]
3. Patterns of Anticoagulation Use and Cardioembolic Risk After Catheter Ablation for Atrial Fibrillation.
Noseworthy PA; Yao X; Deshmukh AJ; Van Houten H; Sangaralingham LR; Siontis KC; Piccini JP; Asirvatham SJ; Friedman PA; Packer DL; Gersh BJ; Shah ND
J Am Heart Assoc; 2015 Nov; 4(11):. PubMed ID: 26541393
[TBL] [Abstract][Full Text] [Related]
4. Long-term risk of stroke and bleeding post-atrial fibrillation ablation.
Joza J; Samuel M; Jackevicius CA; Behlouli H; Jia J; Koh M; Tsadok MA; Tang ASL; Verma A; Pilote L; Essebag V
J Cardiovasc Electrophysiol; 2018 Oct; 29(10):1355-1362. PubMed ID: 30047574
[TBL] [Abstract][Full Text] [Related]
5. Vitamin K antagonists with or without long-term antiplatelet therapy in outpatients with stable coronary artery disease and atrial fibrillation: Association with ischemic and bleeding events.
Lemesle G; Ducrocq G; Elbez Y; Van Belle E; Goto S; Cannon CP; Bauters C; Bhatt DL; Steg PG;
Clin Cardiol; 2017 Oct; 40(10):932-939. PubMed ID: 28692742
[TBL] [Abstract][Full Text] [Related]
6. Anticoagulation after catheter ablation of atrial fibrillation: An unnecessary evil? A systematic review and meta-analysis.
Proietti R; AlTurki A; Di Biase L; China P; Forleo G; Corrado A; Marras E; Natale A; Themistoclakis S
J Cardiovasc Electrophysiol; 2019 Apr; 30(4):468-478. PubMed ID: 30575175
[TBL] [Abstract][Full Text] [Related]
7. Anticoagulation use and clinical outcomes after catheter ablation in patients with persistent and longstanding persistent atrial fibrillation.
Liang JJ; Elafros MA; Mullen MT; Muser D; Hayashi T; Enriquez A; Pathak RK; Zado ES; Santangeli P; Arkles JS; Schaller RD; Supple GE; Frankel DS; Garcia FC; Deo R; Lin D; Riley MP; Nazarian S; Dixit S; Marchlinski FE; Callans DJ
J Cardiovasc Electrophysiol; 2018 Jun; 29(6):823-832. PubMed ID: 29513397
[TBL] [Abstract][Full Text] [Related]
8. Discontinuation of oral anticoagulation and risk of stroke and death after ablation for typical atrial flutter: A nation-wide Danish cohort study.
Giehm-Reese M; Johansen MN; Kronborg MB; Jensen HK; Gerdes C; Kristensen J; Johannessen A; Jacobsen PK; Djurhuus MS; Hansen PS; Riahi S; Nielsen JC
Int J Cardiol; 2021 Jun; 333():110-116. PubMed ID: 33647366
[TBL] [Abstract][Full Text] [Related]
9. The impact of risk score (CHADS2 versus CHA2DS2-VASc) on long-term outcomes after atrial fibrillation ablation.
Jacobs V; May HT; Bair TL; Crandall BG; Cutler M; Day JD; Weiss JP; Osborn JS; Muhlestein JB; Anderson JL; Mallender C; Bunch TJ
Heart Rhythm; 2015 Apr; 12(4):681-6. PubMed ID: 25546809
[TBL] [Abstract][Full Text] [Related]
10. Successful catheter ablation reduces the risk of cardiovascular events in atrial fibrillation patients with CHA2DS2-VASc risk score of 1 and higher.
Lin YJ; Chao TF; Tsao HM; Chang SL; Lo LW; Chiang CE; Hu YF; Hsu PF; Chuang SY; Li CH; Chung FP; Chen YY; Wu TJ; Hsieh MH; Chen SA
Europace; 2013 May; 15(5):676-84. PubMed ID: 23193161
[TBL] [Abstract][Full Text] [Related]
11. Rationale and design of AXAFA-AFNET 5: an investigator-initiated, randomized, open, blinded outcome assessment, multi-centre trial to comparing continuous apixaban to vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation.
Di Biase L; Callans D; Hæusler KG; Hindricks G; Al-Khalidi H; Mont L; Cosedis Nielsen J; Piccini JP; Schotten U; Kirchhof P
Europace; 2017 Jan; 19(1):132-138. PubMed ID: 28130378
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of Patients With Atrial Fibrillation Newly Recommended for Oral Anticoagulation Under the 2014 American Heart Association/American College of Cardiology/Heart Rhythm Society Guideline.
Gray MP; Saba S; Zhang Y; Hernandez I
J Am Heart Assoc; 2018 Jan; 7(1):. PubMed ID: 29301756
[TBL] [Abstract][Full Text] [Related]
13. Reasons for and consequences of oral anticoagulant underuse in atrial fibrillation with heart failure.
Savarese G; Sartipy U; Friberg L; Dahlström U; Lund LH
Heart; 2018 Jul; 104(13):1093-1100. PubMed ID: 29371374
[TBL] [Abstract][Full Text] [Related]
14. "As Needed" nonvitamin K antagonist oral anticoagulants for infrequent atrial fibrillation episodes following atrial fibrillation ablation guided by diligent pulse monitoring: A feasibility study.
Zado ES; Pammer M; Parham T; Lin D; Frankel DS; Dixit S; Marchlinski FE
J Cardiovasc Electrophysiol; 2019 May; 30(5):631-638. PubMed ID: 30706975
[TBL] [Abstract][Full Text] [Related]
15. The safety of discontinuation of oral anticoagulation therapy after apparently successful atrial fibrillation ablation: a report from the Chinese Atrial Fibrillation Registry study.
Yang WY; Du X; Jiang C; He L; Fawzy AM; Wang L; Liu C; Xia SJ; Chang SS; Guo XY; Li SN; Tang RB; Liu N; Bai R; Sang CH; Jiang CX; Yu RH; Long DY; Dong JZ; Lip GYH; Ma CS
Europace; 2020 Jan; 22(1):90-99. PubMed ID: 31909431
[TBL] [Abstract][Full Text] [Related]
16. Oral anticoagulation after catheter ablation of atrial fibrillation and the associated risk of thromboembolic events and intracranial hemorrhage: A systematic review and meta-analysis.
Romero J; Cerrud-Rodriguez RC; Diaz JC; Rodriguez D; Arshad S; Alviz I; Cerna L; Rios S; Monhanty S; Natale A; Garcia MJ; Di Biase L
J Cardiovasc Electrophysiol; 2019 Aug; 30(8):1250-1257. PubMed ID: 31257677
[TBL] [Abstract][Full Text] [Related]
17. Site Variation and Outcomes for Antithrombotic Therapy in Atrial Fibrillation Patients After Percutaneous Coronary Intervention.
Olivier CB; Fan J; Askari M; Mahaffey KW; Heidenreich PA; Perino AC; Leef GC; Ho PM; Harrington RA; Turakhia MP
Circ Cardiovasc Interv; 2019 Aug; 12(8):e007604. PubMed ID: 31416357
[TBL] [Abstract][Full Text] [Related]
18. Comparison of CHADS2 and CHA2DS2-VASC anticoagulation recommendations: evaluation in a cohort of atrial fibrillation ablation patients.
Winkle RA; Mead RH; Engel G; Kong MH; Patrawala RA
Europace; 2014 Feb; 16(2):195-201. PubMed ID: 24036378
[TBL] [Abstract][Full Text] [Related]
19. Catheter Ablation Improves Mortality and Other Outcomes in Real-World Patients With Atrial Fibrillation.
Yang PS; Sung JH; Jang E; Yu HT; Kim TH; Uhm JS; Kim JY; Pak HN; Lee MH; Joung B
J Am Heart Assoc; 2020 Jun; 9(11):e015740. PubMed ID: 32427022
[TBL] [Abstract][Full Text] [Related]
20. Risks and benefits of anticoagulation in atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry.
Cullen MW; Kim S; Piccini JP; Ansell JE; Fonarow GC; Hylek EM; Singer DE; Mahaffey KW; Kowey PR; Thomas L; Go AS; Lopes RD; Chang P; Peterson ED; Gersh BJ;
Circ Cardiovasc Qual Outcomes; 2013 Jul; 6(4):461-9. PubMed ID: 23759473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
